← Celldex Therapeutics, Inc. (CLDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Celldex Therapeutics, Inc. (CLDX)
In Vitro & In Vivo Diagnostic Substances · market cap $2.4B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
17
programs
Upcoming events
6
next 90d+
Dossier
Ready
cached
Celldex Therapeutics (CLDX) is a clinical-stage biotech with a $3.0B market cap and a broad oncology/immunology pipeline anchored by barzolvolimab in Phase 3 for Prurigo Nodularis — the highest-importance catalyst on the horizon. The company carries a critically thin cash position of $35.7M with an estimated 1.6-month runway, making near-term capital raising an existential necessity rather than a contingency.
The catalyst path
- 2026-10-15 (est.)Phase 2 · barzolvolimabimp 7/10
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · CDX-301imp 7/10
- 2027-01-01Phase 3imp 8/10
- 2027-03-15 (est.)Phase 2 · Anti-CD40 Agonist Monoclonal Antibody CDX-1140imp 7/10
- 2027-03-31 (est.)Phase 2 · Human CMV pp65-LAMP mRNA-pulsed autologous DCsimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rindopepimut (CDX-110) with GM-CSF | Phase 3 | Glioblastoma |
| 6MHP | Phase 2 | Melanoma |
| CDX-1401 in combination with Resiquimod and/or Poly-ICLC | Phase 2 | Advanced Malignancies |
| CDX-011 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer |
| barzolvolimab | Phase 3 | Prurigo Nodularis |
| CDX-110 with GM-CSF | Phase 2 | Malignant Glioma |
| "Investigator's Choice" chemotherapy | Phase 2 | Breast Cancer |
| NeoAg-mBRAF | Phase 2 | Melanoma |
| FLT3 Ligand Therapy (CDX-301) | Phase 2 | Non-small Cell Lung Cancer (NSCLC) |
| Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Phase 2 | Glioblastoma |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | Phase 2 | Fallopian Tube Carcinoma |
| Varlilumab | Phase 2 | B Cell Lymphoma |
| CDX-301 | Phase 2 | Breast Cancer |
| rhuFlt3L/CDX-301 | Phase 2 | Low-Grade B-cell Lymphoma |
| Flt3L | Phase 2 | Non-Hodgkin's Lymphoma |
| Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Phase 2 | Ovarian Clear Cell Adenocarcinoma |
| KLH | Phase 3 | Glioblastoma |
Price & technical context
3-month
-16.1%
6-month
+2.9%
12-month
+27.2%
52-wk range
$22.58–$44.87
vs 50-day MA
-16.1%
vs 200-day MA
-0.4%
Realized vol
51.0%
Max drawdown
-65.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CLDX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.